



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Brad A. Marder
✉ bmarder@amgen.com

RECEIVED 18 March 2025
ACCEPTED 25 March 2025
PUBLISHED 03 April 2025

CITATION
Abdellatif A, Zhao L, Obermeyer K,
Vranic Z, Marder BA and Scandling JD
(2025) Corrigendum: Quality of life
improvements and clinical assessments in
kidney transplant recipients undergoing
pegloticase treatment for uncontrolled gout:
findings of the phase 4 PROTECT clinical trial.
Front. Immunol. 16:1595951.
doi: 10.3389/fimmu.2025.1595951

COPYRIGHT
© 2025 Abdellatif, Zhao, Obermeyer, Vranic,
Marder and Scandling. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial

Abdul Abdellatif¹, Lin Zhao², Katie Obermeyer², Zana Vranic²,
Brad A. Marder^{2*} and John D. Scandling³

¹Department of Medicine, Division of Nephrology at CLS Health and Baylor College of Medicine, Houston, TX, United States, ²Rare Disease Unit, Amgen Inc. (formerly Horizon Therapeutics), Thousand Oaks, CA, United States, ³Division of Nephrology, Stanford School of Medicine, Stanford, CA, United States

KEYWORDS

gout, kidney transplant, urate, quality of life, renal function, blood pressure

A Corrigendum on

Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial

by Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025). *Front. Immunol.* 16:1516146. doi: 10.3389/fimmu.2025.1516146

In the published article, the reference for “The high impact of gout on lowering patient QOL is well established, and these effects are more pronounced in KT recipients” was incorrectly written as “40”. It should be “14”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.